Applied DNA Positions TR8 PGx Testing Service as Pre-emptive Testing for Safety of Fluoropyrimidine-Based Cancer Therapeutics Following Publication of Food and Drug Administration Safety Announcement
April 1st, 2025
All Categories
ACDL
APDN in the News
CertainT®
Coronavirus
Corporate/Financial News
Investors
Large-Scale DNA Production
Linear DNA
mpox
PGx
Press Release
Uncategorized
Vaccines
Category: ACDL
Applied DNA Submits Validation Package to New York State Department of Health for H5 Bird Flu/Pan-Influenza A Laboratory-Developed Test
March 26th, 2025
Applied DNA Launches Mpox Clade I and Clade II Testing Service
September 17th, 2024
Applied DNA Submits Validation Package to New York State Department of Health to Expand Linea Mpox Virus 1.0 Assay to Mpox Clade I
August 23rd, 2024
Applied DNA To Submit Application to New York State Department of Health to Expand Intended Use of Linea Mpox Virus 1.0 Assay to Mpox Clade I
August 19th, 2024
Applied DNA Partners with GenXys Health Care Systems to Deploy Clinical Decision Support System for Pharmacogenetic (PGx) Testing
June 18th, 2024
Applied DNA Receives Approval for TR8™ Pharmacogenomic (PGx) Testing Service from New York State Department of Health
June 13th, 2024
APDN Submits Validation Package to NYS DOH for Approval of PGx Assay
March 22nd, 2023
COVID-19 Surveillance Testing at SBUH
November 10th, 2020